Research programme: antibody therapeutics - F-star

Drug Profile

Research programme: antibody therapeutics - F-star

Alternative Names: Fcab - F-star; Fcab antibody fragments - F-star; FS 101; FS 117; FS 17; FS 18; FS 20; FS 22; FS-118; LAG-3/PD-L1 bispecific antibody - F-star; LAG-3/PD-L1 mAb²; mAb²TM

Latest Information Update: 12 Jun 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator f-star
  • Class Antineoplastics; Bispecific antibodies; Immunoconjugates
  • Mechanism of Action Apoptosis stimulants; CD223 antigen inhibitors; CD274 antigen inhibitors; Checkpoint kinase inhibitors; Epidermal growth factor inhibitors; ERBB 2 receptor antagonists; Hepatocyte growth factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 04 Jun 2017 Merck KGaA and f-star enter an option agreement for FS 118 and antibody therapeutics
  • 05 Apr 2017 Pharmacodynamics data from a preclinical trial in Cancer presented at the American Association for Cancer Research Annual Meeting (AACR-2017)
  • 05 Aug 2016 F-star and Ligand Pharmaceuticals enter into an agreement to discover human mono and bi-specific antibodies utilising Ligand's OmniAb platform, before August 2015
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top